Strategic collaborations There are multiple high-profile partnerships and alliances announced in 2026 with Globalalzplatform, Decode Health, Vitazi.ai, and others, plus a notable Nature Medicine finding. This suggests opportunity to engage through co-development or joint go-to-market initiatives, leveraging CircPATH and multimodal workflows to expand adoption across neurology and neurodegenerative disease care pathways.

Clinical impact evidence CircPATH and accompanying biomarker studies demonstrate improved prediction of Alzheimer’s progression, supported by Nature Medicine publication. This strengthens the value proposition for payors, clinics, and diagnostic labs seeking precision neurology tools, creating opening for pilots, reimbursement discussions, and expanded clinical use cases.

Early-stage expansion The company is actively expanding its product suite and geographic reach, with new scientific advisory appointments and rapid product launches in 2026. This timing presents opportunities to introduce complementary services such as biomarker profiling, assay deployment, and regulatory-ready workflows to customers pursuing early detection and risk stratification.

Funding momentum A successful Series A funding round of 15 million and total funding around 28 million indicate financial backing and growth trajectory. This signals willingness to engage in strategic partnerships, co-development deals, and enterprise-level deployments that require scalable support and long-term commitments.

Tech-enabled delivery The tech stack and data-driven platform focus, including circRNA discovery, AI-enabled integration with other datasets, and cloud-based workflows, point to opportunities to offer implementation services, data integration, managed analytics, and personalized care pathway optimization for neurology clinics and research partners.